Afb Rrna Detection Tma Synovial Fluid

The Hologic Amplified Mycobacterium Tuberculosis Direct (MTD) Test is a target-amplified nucleic acid probe test for the in vitro diagnostic detection of Mycobacterium tuberculosis complex ribosomal ribonucleic acid (rRNA) in acid-fast bacilli (AFB) smear positive and negative concentrated sediments prepared from sputum (induced or expectorated), bronchial specimens (e.g., bronchoalveolar lavages or bronchial aspirates) or tracheal aspirates. The Amplified MTD test is intended for use only with specimens from patients showing signs and symptoms consistent with active pulmonary tuberculosis (TB). MTD is to be used as an adjunctive test for evaluating either AFB smear positive or negative sediments prepared using NALC-NaOH digestion-decontamination of respiratory specimens. Patients who are suspected of having pulmonary TB based on clinical evaluation and who have received no antituberculous therapy, less than 7 days of such therapy, or have not received such therapy in the last 12 months may be evaluated with this test. The MTD test should be performed only in laboratories proficient in the culture and identification of M. tuberculosis (Level II and III or extent 3 and 4). The MTD test must be performed in conjunction with mycobacterial culture. The MTD test utilizes Transcription-Mediated Amplification (TMA) and HPA to qualitatively detect M. tuberculosis complex rRNA. The MTD test will detect rRNA from both cultivable and non-cultivable organisms. Organisms of the M. tuberculosis complex include M. tuberculosis, M. bovis, M. bovis BCG, M. africanum, M. microti, M. canetti, and M. pinnipedii. The MTD test can detect all organisms within the M. tuberculosis complex.